February 10, 2017 07:17 AM EST

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

You can count Seattle Genetics as the new flag carrier for Immunomedics’ solid tumor drug IMMU-132. The biotech is paying $300 million to claim …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seat­tle Ge­net­ics grabs Im­munomedics’ tu­mor drug in $2B deal, shoot­ing for a quick OK